title: Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patients with type II diabetes mellitus.
abstract: The potential for eprosartan, a nonbiphenyl tetrazole angiotensin II receptor antagonist, to affect the 24-hour plasma glucose profiles in type II diabetic patients treated with glyburide was investigated in this randomized, placebo-controlled, double-blind (eprosartan-placebo phase only), two-period, period-balanced, crossover study. All patients received a stable oral dose (3.75-10 mg/day) of glyburide for at least 30 days before the first dose of double-blind study medication was administered. Patients were randomized to receive either 200-mg oral doses of eprosartan twice daily or matching oral placebo doses concomitantly with glyburide for 7 days during each treatment period. After a minimum washout period of 14 days, patients were crossed over to the alternate treatment. Serial samples to measure glucose concentrations in plasma were collected over a 24-hour period on the day before administration of eprosartan or placebo and again on day 7. Mean glucose concentrations were comparable between treatment groups before administration of eprosartan or placebo. The point estimate (90% confidence interval) for the ratio of the average mean 24-hour plasma glucose concentrations of eprosartan + glyburide to placebo + glyburide after 7 days of administration was 0.96 (0.90, 1.01). Eprosartan did not significantly alter the 24-hour plasma glucose profile in patients with type II diabetes mellitus who were previously stabilized on glyburide.
authors.affiliation: SmithKline Beecham Clinical Pharmacology Unit, Presbyterian Medical Center of Philadelphia, University of Pennsylvania Health System, Philadelphia 19104, USA.
authors.forename: D E
authors.initials: DE
authors.lastname: Martin
authors.forename: G S
authors.initials: GS
authors.lastname: DeCherney
authors.forename: B E
authors.initials: BE
authors.lastname: Ilson
authors.forename: B A
authors.initials: BA
authors.lastname: Jones
authors.forename: S C
authors.initials: SC
authors.lastname: Boike
authors.forename: M I
authors.initials: MI
authors.lastname: Freed
authors.forename: D K
authors.initials: DK
authors.lastname: Jorkasky
mesh_terms: D000179:Acrylates / Q000009:adverse effects / Q000494:pharmacology*; D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000494:pharmacology*; D001786:Blood Glucose / Q000187:drug effects; D018592:Cross-Over Studies; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000378:metabolism*; D004311:Double-Blind Method; D004347:Drug Interactions; D005260:Female; D005905:Glyburide / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007093:Imidazoles / Q000009:adverse effects / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D013546:Sweating; D013876:Thiophenes
chemical_list: D000179:Acrylates; D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007093:Imidazoles; D013876:Thiophenes; C068373:eprosartan; D005905:Glyburide